State Medicaid Rx Cost Control Tools To Be Evaluated By IG In FY 2003
Executive Summary
HHS' Office of the Inspector General plans to evaluate state programs aimed at controlling Medicaid prescription drugs costs during FY 2003
You may also be interested in...
Medicaid Rx Four-Tier Reimbursement System Recommended By HHS IG
Medicaid reimbursement for prescription drugs should be based on a four-tier system to more accurately reflect pharmacies' actual acquisition costs, the HHS Inspector General recommends in a Sept. 16 report
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials